Known targets — ChEMBL curated mechanism
CACNA1CCACNA1DCACNA1FCACNA1SDPP4HTR1BHTR1D
The experimentally established mechanism targets of Benzoic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 14/20 | 0.94 |
| ▸ | CA4 | P22748 | 1/20 | 0.94 |
| ▸ | CA1 | P00915 | 13/20 | 0.56 |
| ▸ | CES2 | O00748 | 2/20 | 0.52 |
| ▸ | CES1 | P23141 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | DAO | P14920 | 1/20 | 0.52 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzoic Acid SCHEMBL8032290 | 0.97 | CA2 (0.90) | CA2CA4CA1CES2CES1 | |
| Benzoic Acid SCHEMBL7116782 | 0.97 | CA2 (0.90) | CA2CA4CA1CES2CES1 | |
| Benzoic Acid SCHEMBL27711371 | 0.97 | CA2 (1.00) | CA2CA4CA1CES2CES1 | |
| Benzoic Acid SCHEMBL29175054 | 0.97 | CA2 (1.00) | CA2CA4CA1CES2CES1 | |
| Benzoic Acid SCHEMBL431405 | 0.97 | CA2 (1.00) | CA2CA4CA1CES2CES1 | |
| Benzoic Acid SCHEMBL29053363 | 0.97 | CA2 (1.00) | CA2CA4CA1CES2CES1 | |
| Benzoic Acid SCHEMBL6123440 | 0.97 | CA2 (1.00) | CA2CA4CA1CES2CES1 | |
| Benzoic Acid SCHEMBL16115635 | 0.97 | CA2 (1.00) | CA2CA4CA1CES2CES1 | |
| Benzoic Acid SCHEMBL28946409 | 0.97 | CA2 (1.00) | CA2CA4CA1CES2CES1 | |
| Benzoic Acid SCHEMBL823 | 0.97 | CA2 (1.00) | CA2CA4CA1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2698145-B1 | Pharmaceutical Formulations comprising dapoxetine and a PDE5 inhibitor | MONTERO GIDA SANAYI VE TICARET AS (TR) | 2020-12-02 | — | — | EP | claimed |
| US-20160008375-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING QUETIAPINE AND ESCITALOPRAM | SANOVEL ILAC SANAYI VE TICARET A.S. (TR) | 2016-01-14 | — | — | US | claimed |
| EP-2961390-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING QUETIAPINE AND ESCITALOPRAM | Sanovel Ilac Sanayi ve Ticaret A.S. (TR) | 2016-01-06 | — | — | EP | claimed |
| EP-2956125-A1 | ORAL PHARMACEUTICAL FORMULATIONS COMPRISING NIMESULIDE AND THIOCOLCHICOSIDE | Sanovel Ilac Sanayi ve Ticaret A.S. (TR) | 2015-12-23 | — | — | EP | claimed |
| EP-2793853-B1 | PHARMACEUTICAL FORMULATIONS OF FLURBIPROFEN AND GLUCOSAMIN | SANOVEL ILAC SANAYI VE TICARET (TR) | 2015-12-16 | — | — | EP | claimed |
| US-20150216798-A1 | NOVEL ORALLY ADMINISTERED PHARMACEUTICAL FORMULATIONS | SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI (TR) | 2015-08-06 | — | — | US | claimed |
| US-20150196506-A1 | CHEWING GUM FORMULATIONS COMPRISING DAPOXETINE AND TADALAFIL | Sanovel llac Sanayi Ve Ticaret Anonim Sirketi (TR) | 2015-07-16 | — | — | US | claimed |
| US-20150010627-A1 | NEW PHARMACEUTICAL COMPOSITIONS OF FLURBIPROFEN AND GLUCOSAMIN | SANOVEL ILAC SANAYI VE TICARET (TR) | 2015-01-08 | — | — | US | claimed |
| US-20140363508-A1 | PHARMACEUTICAL FORMULATIONS OF FLURBIPROFEN AND GLUCOSAMIN | SANOVEL SANAYI VE TICARET ANONIM SIRKETI (TR) | 2014-12-11 | — | — | US | claimed |
| EP-2809306-A2 | NEW PHARMACEUTICAL COMPOSITIONS OF FLURBIPROFEN AND GLUCOSAMIN | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi (TR) | 2014-12-10 | — | — | EP | claimed |
| EP-2394638-B1 | New pharmaceutical combinations | SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI (TR) | 2013-05-08 | — | — | EP | claimed |
| EP-2547330-A2 | ORALLY DISINTEGRATING TABLET FORMULATIONS OF DONEPEZIL AND PROCESS FOR PREPARING THE SAME | Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi (TR) | 2013-01-23 | — | — | EP | claimed |
| EP-2468361-A1 | Vildagliptin Formulations | Sanovel Ilac Sanayi ve Ticaret A.S. (TR) | 2012-06-27 | — | — | EP | claimed |
| EP-2407159-A1 | Pharmaceutical compositions of olmesartan | Sanovel Ilac Sanayi ve Ticaret A.S. (TR) | 2012-01-18 | — | — | EP | claimed |
| WO-2012005709-A2 | PHARMACEUTICAL COMPOSITION COMPRISING VALSARTAN | BILGIC MAHMUT (TR) | 2012-01-12 | — | — | WO | claimed |
| US-20110305757-A1 | NEW PHARMACEUTICAL COMBINATIONS | SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI (TR) | 2011-12-15 | — | — | US | claimed |
| EP-2394638-A1 | New Pharmaceutical Combinations | Sanovel Ilac Sanayi ve Ticaret A.S. (TR) | 2011-12-14 | — | — | EP | claimed |
| EP-2295040-B1 | Pharmaceutical compositions of pramipexole | SANOVEL ILAC SANAYI VE TICARET AS (TR) | 2011-10-12 | — | — | EP | claimed |
| WO-2011115599-A2 | ORALLY DISINTEGRATING TABLET FORMULATIONS OF DONEPEZIL AND PROCESS FOR PREPARING THE SAME | SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI (TR) | 2011-09-22 | — | — | WO | claimed |
| EP-2295040-A1 | Pharmaceutical compositions of pramipexole | Sanovel Ilac Sanayi ve Ticaret A.S. (TR) | 2011-03-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150010627-A1 | NEW PHARMACEUTICAL COMPOSITIONS OF FLURBIPROFEN AND GLUCOSAMIN | SLC5A1, SLC35B2, SLC5A2 | CA2 535/4885CA4 977/4885CA1 1721/4885 |
| US-20160008375-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING QUETIAPINE AND ESCITALOPRAM | SLC6A4, SLC6A2, SLC6A3 | CA2 2236/4885CA4 1581/4885CA1 3542/4885 |
| US-20110305757-A1 | NEW PHARMACEUTICAL COMBINATIONS | REN, SLC5A1, SLC5A2 | CA2 264/4885CA4 273/4885CA1 2528/4885 |
| US-20150196506-A1 | CHEWING GUM FORMULATIONS COMPRISING DAPOXETINE AND TADALAFIL | PDE5A, PDE3A, PDE3B | CA2 3100/4885CA4 2346/4885CA1 4150/4885 |
| US-20140363508-A1 | PHARMACEUTICAL FORMULATIONS OF FLURBIPROFEN AND GLUCOSAMIN | SLC5A1, SLC2A3, SLC2A1 | CA2 509/4885CA4 824/4885CA1 1789/4885 |
| US-20150216798-A1 | NOVEL ORALLY ADMINISTERED PHARMACEUTICAL FORMULATIONS | PDE5A, PDE12, PDE3A | CA2 2184/4885CA4 2586/4885CA1 4508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.